The poorer prognosis of TNBC is in part due to lack of targeted therapy compared to other molecular subtypes managed with hormonal therapy like tamoxifen and aromatase inhibitors that treat hormone receptor-positive cancers and targeted therapies like trastuzumab and pertuzumab that treat HER2/neu + cancers.11 This evidence concerns the gene ERBB2 and cancer.